Clinical and Translational Oncology Clinical and Translational Oncology RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Neoadjuvant chemoimmunotherapy shows major pathological response and low recurrence in head and neck squamous cell carcinoma
ConclusionNeoadjuvant chemoimmunotherapy of HNSCC showed high rate of pathological response and low recurrence rate, holding promise for becoming the new standard of care for resectable HNSCC. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - April 22, 2024 Category: Cancer & Oncology Source Type: research

A genetic profiling guideline to support diagnosis and clinical management of lymphomas
AbstractThe new lymphoma classifications (International Consensus Classification of Mature Lymphoid Neoplasms, and 5th World Health Organization Classification of Lymphoid Neoplasms) include genetics as an integral part of lymphoma diagnosis, allowing better lymphoma subclassification, patient risk stratification, and prediction of treatment response. Lymphomas are characterized by very few recurrent and disease-specific mutations, and most entities have a heterogenous genetic landscape with a long tail of recurrently mutated genes. Most of these occur at low frequencies, reflecting the clinical heterogeneity of lymphomas....
Source: Clinical and Translational Oncology - April 22, 2024 Category: Cancer & Oncology Source Type: research

Current status of fertility preservation in a Spanish tertiary public hospital: multidisciplinary approach and experience in over 1500 patients
ConclusionsThe increase in FP treatment reflects the implementation of reproductive counselling in oncology programmes. A multidisciplinary approach in a tertiary public hospital allows individualised FP treatment for each patient. In recent years, there has been a change in trend with the introduction of new indications for FP and a change in techniques due to their optimisation. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - April 22, 2024 Category: Cancer & Oncology Source Type: research

Immunoradiotherapy for NSCLC: mechanisms, clinical outcomes, and future directions
AbstractNon-small-cell lung cancer (NSCLC) has an extremely low 5-year survival rate, with the only effective treatment being immunoradiotherapy (iRT). Here, we review the progress of clinical research on iRT for non-small-cell lung cancer (NSCLC) over 2018 –2023, as well as the future directions. We first discuss the synergistic mechanisms of iRT, reflected in three aspects: immune regulation of RT, RT-activated immune-related pathways, and RT-related immune sensitization. iRT may include either external-beam or stereotactic-body RT combined with ei ther immune checkpoint inhibitors (e.g., immunoglobulins against immune...
Source: Clinical and Translational Oncology - April 22, 2024 Category: Cancer & Oncology Source Type: research

Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?
ConclusionsDespite the definition of a life expectancy of  >  3 months as a standard inclusion criterion in clinical trials for advanced PC, a significant proportion of study patients does not survive >  3 months.Trial registration numbersNCT00440167 (AIO-PK0104), NCT01729481 (RASH), NCT01728818 (ACCEPT). (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - April 22, 2024 Category: Cancer & Oncology Source Type: research

Exploring the time-dependent regulatory potential of microRNAs in breast cancer cells treated with proteasome inhibitors
ConclusionsThe diversity of pathways predicted to be affected by the diversity in miRNA expression after treatment with PIs paves the way for the recognition of new regulatory axes in BrCa. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - April 22, 2024 Category: Cancer & Oncology Source Type: research

Sexual dysfunction in patients with cancer, a challenge in oncology practice: results of the CLARIFY project
ConclusionsOur population has a high prevalence of SD, which supports the need to increase awareness of this disorder among the medical oncology team and the importance of including sexual health assessment in oncological patient follow-up. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - April 22, 2024 Category: Cancer & Oncology Source Type: research

A gastric sarcoma from 3000  years ago: paleopathological diagnosis at the field
ConclusionsMalignant diseases are seldom described in Paleopathology; to our knowledge, this is the oldest and most unique case of this type of pathology in mummies worldwide. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - April 22, 2024 Category: Cancer & Oncology Source Type: research

Predictive value of NLR and PLR for immune-related adverse events: a systematic review and meta-analysis
ConclusionsBoth L-NLR and L-PLR have been found to be significantly associated with irAEs. Consequently, patients identified as being at a higher risk for irAEs should be subjected to more diligent monitoring and close observation. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - April 22, 2024 Category: Cancer & Oncology Source Type: research

Endometrial cancer: predictors and oncological safety of tumor tissue manipulation
ConclusionWhilst performing common gynecological procedures, iatrogenic distention and manipulation of the uterine cavity are produced. Our study suggests that the use of uterine manipulator increases the rate of LVSI and, therefore, leads to poorer oncological results. Conversely, preoperative hysteroscopy does not show higher rates of LVSI involvement in the final surgical specimen and can be safely used. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - April 22, 2024 Category: Cancer & Oncology Source Type: research

Distribution of PD-L1, TROP2 and HER2- “lowness” in early triple-negative breast cancer: an opportunity for treatment de-escalation
ConclusionsEarly HER2-low, PD-L1-positive TNBC patients have a very good prognosis, particularly if treated with anthracycline/taxane- or carboplatin-containing regimes. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - April 22, 2024 Category: Cancer & Oncology Source Type: research

Anoikis patterns via machine learning strategy and experimental verification exhibit distinct prognostic and immune landscapes in melanoma
ConclusionsIn this study, we successfully established a prognostic anoikis-connected signature using machine learning. This model may aid in evaluating patient prognosis, clinical characteristics, and immune treatment modalities for melanoma. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - April 22, 2024 Category: Cancer & Oncology Source Type: research

Early kinetics of C-reactive protein as prognosticator for survival in a real-world cohort of patients with metastatic renal cell cancer under first-line therapy with immune checkpoint inhibitors
ConclusionsThe present study emphasizes the prognostic potential of early CRP kinetics in CPI-treated mRCC. As a standard laboratory parameter, CRP can be easily implemented into clinical routine to facilitate therapy monitoring. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - April 22, 2024 Category: Cancer & Oncology Source Type: research

Biologically effective dose (BED) value lower than 120  Gy improve outcomes in lung SBRT
ConclusionOur data suggest that mean total dose lower 54 and a calculated BED  <  120 Gy is the optimal. Further prospective data are needed to confirm these results and determine the optimal dose fractionation scheme as a function of tumor size and location of volume. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - April 22, 2024 Category: Cancer & Oncology Source Type: research

Impact of 18F-FDG PET/CT in the management decisions of breast cancer board on early-stage breast cancer
ConclusionsIn conclusion, this study highlights the importance of adherence to the guidelines and appropriate use of PET/CT in early-stage breast cancer management. PET/CT should be reserved for cases where it is clinically warranted, considering the potential economic burden and minimal impact on treatment decisions of breast cancer tumor board in this patient population. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - April 22, 2024 Category: Cancer & Oncology Source Type: research